The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Vipoma


High impact information on Vipoma


Chemical compound and disease context of Vipoma


Anatomical context of Vipoma


Gene context of Vipoma


Analytical, diagnostic and therapeutic context of Vipoma


  1. Experimental evidence for vasoactive intestinal peptide as the cause of the watery diarrhea syndrome. Modlin, I.M., Bloom, S.R., Mitchell, S.J. Gastroenterology (1978) [Pubmed]
  2. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Kraenzlin, M.E., Ch'ng, J.L., Wood, S.M., Carr, D.H., Bloom, S.R. Gastroenterology (1985) [Pubmed]
  3. Clonidine and lidamidine to inhibit watery diarrhea in a patient with lung cancer. McArthur, K.E., Anderson, D.S., Durbin, T.E., Orloff, M.J., Dharmsathaphorn, K. Ann. Intern. Med. (1982) [Pubmed]
  4. Expression of peptide receptors in human endocrine tumours of the pancreas. Tang, C., Biemond, I., Lamers, C.B. Gut (1997) [Pubmed]
  5. Somatostatin analogue: use in the treatment of vipoma with hypercalcemia. Venkatesh, S., Vassilopoulou-Sellin, R., Samaan, N.A. Am. J. Med. (1989) [Pubmed]
  6. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. Maton, P.N., O'Dorisio, T.M., Howe, B.A., McArthur, K.E., Howard, J.M., Cherner, J.A., Malarkey, T.B., Collen, M.J., Gardner, J.D., Jensen, R.T. N. Engl. J. Med. (1985) [Pubmed]
  7. VIP and the pancreatic cholera syndrome. Verdin, E.M., Green, F.W. N. Engl. J. Med. (1984) [Pubmed]
  8. Pancreatic cholera: is the diarrhea due to VIP? Field, M., Chang, E.B. N. Engl. J. Med. (1983) [Pubmed]
  9. Lithium carbonate in pancreatic cholera. Graham, D.Y. N. Engl. J. Med. (1980) [Pubmed]
  10. Indomethacin-responsive pancreatic cholera. Jaffe, B.M., Kopen, D.F., DeSchryver-Kecskemeti, K., Gingerich, R.L., Greider, M. N. Engl. J. Med. (1977) [Pubmed]
  11. Pancreatic cholera: benefical effects of treatment with streptozotocin. Kahn, C.R., Levy, A.G., Gardner, J.D., Miller, J.V., Gorden, P., Schein, P.S. N. Engl. J. Med. (1975) [Pubmed]
  12. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Clements, D., Elias, E. Lancet (1985) [Pubmed]
  13. Diarrhoea in vipoma patients associated with cosecretion of a second active peptide (peptide histidine isoleucine) explained by single coding gene. Bloom, S.R., Christofides, N.D., Delamarter, J., Buell, G., Kawashima, E., Polak, J.M. Lancet (1983) [Pubmed]
  14. Effects of preprovasoactive intestinal polypeptide-derived peptides on ileal output. Calam, J., Yiangou, Y., Nikou, G.C., Chrysanthou, B.J., Beacham, J.L., Bloom, S.R. Gastroenterology (1990) [Pubmed]
  15. Trifluoperazine reversal of secretory diarrhea in pancreatic cholera. Donowitz, M., Elta, G., Bloom, S.R., Nathanson, L. Ann. Intern. Med. (1980) [Pubmed]
  16. Vipoma of the pancreas: observations on the diarhrhea and circulatory disturbances. Barraclough, M.A., Bloom, S.R. Arch. Intern. Med. (1979) [Pubmed]
  17. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Bartsch, D., Hahn, S.A., Danichevski, K.D., Ramaswamy, A., Bastian, D., Galehdari, H., Barth, P., Schmiegel, W., Simon, B., Rothmund, M. Oncogene (1999) [Pubmed]
  18. The morphology and neuroendocrine profile of pancreatic epithelial VIPomas and extrapancreatic, VIP-producing, neurogenic tumors. Solcia, E., Capella, C., Riva, C., Rindi, G., Polak, J.M. Ann. N. Y. Acad. Sci. (1988) [Pubmed]
  19. Effects of pancreatic polypeptide and vasoactive intestinal polypeptide on rat ileal and colonic water and electrolyte transport in vivo. Wu, Z.C., O'Dorisio, T.M., Cataland, S., Mekhjian, H.S., Gaginella, T.S. Dig. Dis. Sci. (1979) [Pubmed]
  20. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Vinik, A.I., Tsai, S.T., Moattari, A.R., Cheung, P., Eckhauser, F.E., Cho, K. Am. J. Med. (1986) [Pubmed]
  21. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours. Stridsberg, M., Eriksson, B., Lundqvist, G., Skogseid, B., Wilander, E., Oberg, K. Regul. Pept. (1995) [Pubmed]
  22. Occurrence of human pancreatic polypeptide in pancreatic endocrine tumors. Possible implication in the watery diarrhea syndrome. Larsson, L.I., Schwartz, T., Lundqvist, G., Chance, R.E., Sundler, F., Rehfeld, J.F., Grimelius, L., Fahrenkrug, J., Schaffalitzky de Muckadell, O., Moon, N. Am. J. Pathol. (1976) [Pubmed]
  23. Vasoative intestinal peptide and the watery diarrhea syndrome. Ebeid, A.M., Murray, P.D., Fischer, J.E. Ann. Surg. (1978) [Pubmed]
  24. Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-alpha and 5-fluorouracil. Cellier, C., Yaghi, C., Cuillerier, E., Siauve, N., Berger, A., Carnot, F., Haddad, C., Barbier, J.P., Landi, B. Am. J. Gastroenterol. (2000) [Pubmed]
  25. Effect of somatostatin infusion on VIP-induced transport changes in the human jejunum. Krejs, G.J. Peptides (1984) [Pubmed]
  26. Liver VIPoma: report of two cases and literature review. Lundstedt, C., Linjawi, T., Amin, T. Abdominal imaging. (1994) [Pubmed]
WikiGenes - Universities